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Perspective
D
iabetes mellitus is the most 
common endocrine disease 
in the world. The World 
Health Organization estimates that the 
disease is responsible for about 5% of 
all deaths globally each year, a figure 
that is projected to increase by 50% 
within a decade (http://www.who.int/
diabetes/en/). Diabetes mellitus is 
easily diagnosed by the characteristic 
chronic elevation in blood glucose 
concentration, but is in fact merely an 
umbrella diagnosis with several disease 
subtypes.
Failing Insulin Secretion in Type 2 
Diabetes
These subtypes of diabetes mellitus 
are remarkably different in terms of 
pathogenic mechanisms and severity 
of disease, but converge on the 
insufficient release of the glucose-
lowering hormone insulin in the 
beta-cells of the pancreatic islets. The 
by far most common disease variant, 
obesity-related type 2 diabetes, also 
follows this final pathogenic pathway, 
as clearly shown by the United 
Kingdom Prospective Diabetes Study 
[1] and recently underscored by 
genome-wide association scans that 
identified an array of pancreatic 
islet-related genes associating with 
type 2 diabetes (reviewed in [2]). 
Accordingly, sulfonylureas, a group of 
insulin secretagogues, have long been 
cornerstones in the pharmacological 
treatment of type 2 diabetes. These 
compounds bypass the normal 
glucose-sensing mechanism in the 
pancreatic beta-cells and thereby 
initiate insulin secretion. This effect 
is mediated by closure of the ATP-
sensitive potassium channels (KATP
channels) in the beta-cell membrane, 
leading to membrane depolarization, 
opening of voltage-gated Ca2+
channels, and finally Ca2+-dependent 
exocytosis of insulin granules [3,4]. As 
a result, blood glucose concentrations 
decrease, the risk for secondary 
vascular complications is lowered, and 
patients experience increased quality 
of life [5]. 
Secondary Failure of Sulfonylurea 
Treatment
Unfortunately, this story does not end 
on a high note. Within a few years of 
starting treatment with sulfonylureas, 
the beta-cells show clear signs of 
fatigue leading to deteriorated blood 
glucose control. Eventually all patients 
need to take daily insulin injections to 
achieve acceptable control over blood 
glucose [6]. The reasons underlying 
this secondary failure have long been 
debated. One hypothesis that has 
attracted considerable interest is the 
notion that sulfonylurea-mediated 
hyperexcitation of beta-cells may 
trigger excitotoxic reactions leading 
to increased rates of beta-cell 
apoptosis [7]. As a result, beta-cell 
mass decreases, and this is seen as the 
major cause of the developing insulin 
deficiency [8].
An alternative scenario is suggested 
by findings in mouse models. Mice 
with reduced KATP channel activity 
show the expected increased beta-cell 
electrical activity and, consequently, 
hypersecretion of insulin [9]. 
Mouse models with complete lack of 
functional KATP channels have been 
generated by ablation of either the K+
channel pore KIR6.2 or the regulatory 
sulfonylurea receptor 1. Surprisingly, 
both models exhibit a paradoxical 
undersecretory phenotype, in spite of 
continuous beta-cell electrical activity 
and an apparently normal pancreatic 
beta-cell mass [10–12]. These 
findings suggest that a bell-shaped 
relationship exists between electrical 
activity and insulin secretion, and 
that hyperexcitation leads to beta-cell 
failure without beta-cell death. 
Using Slow-Release Sulfonylurea 
Pellets in a New In Vivo Model
In this issue of PLoS Medicine, Remedi 
and Nichols have put the latter 
hypothesis up for scrutiny [13]. To this 
end, the authors used a new approach 
and implanted slow-release pellets with 
the sulfonylurea glibenclamide into 
normal mice. After initial stimulation 
of insulin release, the mice quickly 
developed insulinopenia and glucose 
intolerance, and within one week their 
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Linked Research Article
This Perspective discusses the 
following new study published in PLoS
Medicine:
Remedi MS, Nichols CG (2008) 
Chronic antidiabetic sulfonylureas 
in vivo: Reversible effects on mouse 
pancreatic β-cells. PLoS Med 5(10): e206. 
doi:10.1371/journal.pmed.0050206
In a mouse study aiming to understand 
why long-term treatment for type 2 
diabetes with sulfonylureas eventually 
fails, Colin Nichols and Maria Remedi 
suggest that slow restoration of insulin 
secretion may be possible after a drug-
resting period.
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phenotype was reminiscent of that of 
mice without functional KATP channels. 
Glucose-stimulated insulin secretion 
was greatly reduced in pancreatic islets 
freshly isolated from glibenclamide-
treated mice. 
The most significant finding of 
this study is the observation that the 
decreased capacity for insulin secretion 
is readily reversible. In isolated islets it 
was restored within a few hours after 
wash-out of the drug, and in vivo the 
mice regained glucose tolerance one 
month after cessation of glibenclamide 
treatment. These observations, together 
with the failure to detect any signs 
of increased beta-cell apoptosis in 
glibenclamide-treated mice, clearly 
suggest that the suppression of insulin 
secretion is a reversible and functional
phenomenon, i.e., a temporary 
impairment of the beta-cell stimulus-
secretion coupling.
Pros and Cons of the Present Study
The approach chosen in this study 
is deceptively simple and may at first 
not appear to be strikingly innovative. 
However, one major advantage over 
genetically modified mouse models 
is the absence of any effects during 
pancreas development. For example, 
in KATP channel knock-out mice it is 
difficult to rule out the possibilities 
that the developing beta-cell when 
excessively stimulated may react 
by (1) increasing the capacity for 
Ca2+ buffering and/or extrusion, or 
(2) changing expression of any of 
the myriad of proteins involved in 
regulated exocytosis of the insulin 
granules. That said, this new study calls 
for future detailed studies to allow 
identification of a concrete mechanism 
explaining the reversible suppression 
of insulin secretion by long-term 
glibenclamide treatment. 
Clinical Implications
Another attractive feature of the 
experimental model used here is 
the similarity to the treatment given 
to patients with type 2 diabetes. 
The possible clinical implications 
of this study are that failing insulin 
secretion in type 2 diabetes should 
not be treated with pharmacological 
compounds that stimulate insulin 
release in a tonic fashion. Instead, 
preference should be given to 
compounds with short half-life in 
the circulation and compounds 
that enhance normal pulsatile and 
phasic insulin secretion. Remedi and 
Nichols’ study should prompt further 
clinical studies exploring the possible 
advantage of such compounds for 
maintaining an adequate capacity for 
insulin secretion in type 2 diabetes. 
However, mice are not men, and 
the experimental conditions in this 
new study do not fully mimic the 
clinical situation in humans. For 
instance, secondary failure in mouse 
seems to have a much more rapid 
onset than in humans. Furthermore, 
clinical experience does not suggest 
that termination of sulfonylurea 
treatment leads to revitalization of 
insulin secretion in patients with 
secondary failure. These reservations 
notwithstanding, this study provides 
strong evidence for the view that 
previously neglected mechanisms are 
in operation during progression of 
type 2 diabetes, and represents an 
important point of embarkation for 
future work.  
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